AI Stock Memo: RLYB - Rallybio - RankAlpha

RLYB

Rating neutralTentativeAI Memo

Rallybio

As of 2026-04-06/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-04-06 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Near-term leadership gap after Chief Medical Officer departure • 2026-07-05

Expected move: -50%

Biggest risk

Loss of CMO, slow follow-up development for RLYB116, or cash-runway pressure leads to program delays or dilution, driving a material downside to biotech peer multiples.

Invalidation

Break below $4 or thesis failure.

What would change my mind?

RLYB116 translates into a clear development path (partner or internal Phase 2 plan) and the company stabilizes clinical leadership—market re-rates toward analyst upside with multiplex expansion.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-04-06

Base target

p=50%

Bull target

$15

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Near-term leadership gap after Chief Medical Officer departure
Advancement of RLYB116 development after positive Phase 1 data
RLYB116 translates into a clear development path (partner or internal Phase 2 plan) and the company stabilizes clinical leadership—market re-rates toward analyst upside with multiplex expansion.

BearKey bullets

Clinical execution and timing risk for RLYB116
Leadership/management turnover disrupting program timelines
Limited market liquidity and potential dilution need

WatchKey bullets

ANCHOR: {"price": 8.43, "timestamp_utc": "2026-04-02T00:00:00Z", "source": "rankalpha_api_adj_close"} ANALYST_TARGETS_REVIEWED: true My base target (~$8.50) sits near the analyst median (~$8.415) and reflects limited visible near-term commercial optionality; the bull ( $15 ) aligns with the analyst high if clinical advancement/partnering occurs, while the bear ($4) prices prolonged delays or dilution [#SERP-3] [#SERP-10].

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $9 (p=50%)

Bull/Bear spread: -11% / -76%

Vs latest close: Bull -11% · Base -50% · Bear -76%

Scenario probabilities

Bull Target: $15 (p=20%)Base Target: $9 (p=50%)Bear Target: $4 (p=30%)

Commentary

Market tone is cautious-to-neutral: recent positive Phase 1 data created hopeful headlines but disclosure of the CMO departure increased execution risk [#IR-undated] [#8-K-2026-03-31]. Analyst coverage is thin with consensus near the current price, suggesting limited conviction among sell-side participants [#SERP-1] [#SERP-3].

As of 2026-04-06 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

RLYB116 translates into a clear development path (partner or internal Phase 2 plan) and the company stabilizes clinical leadership—market re-rates toward analyst upside with multiplex expansion.

Bear Case

Loss of CMO, slow follow-up development for RLYB116, or cash-runway pressure leads to program delays or dilution, driving a material downside to biotech peer multiples.

Drivers

Scannable catalysts and supporting factors

Near-term leadership gap after Chief Medical Officer departure
Advancement of RLYB116 development after positive Phase 1 data

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-04-06Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$8.42

Range (USD)

$8.08 - $15.00

Count

Query: Rallybio Corp Common (RLYB) analyst consensus price target high low average

Rallybio (RLYB) Stock Forecast & Price Target
Search result #1
The consensus rating for Rallybio is "Neutral", based on insights from 1 analysts. 0 analysts recommend buying the stock, 0 suggest selling, and 2 recommend ...
Open source
Rallybio Corporation: Target Price Consensus and ...
Search result #2
Rallybio Corporation analysts consensus, targets, ratings and recommendations | Nasdaq: RLYB | Nasdaq. ... Evolution of the Average Target: Rallybio Corporation ...
Open source
RLYB / Rallybio Corporation (NasdaqCM) - Forecast, Price ...
Search result #3
The average one-year price target for Rallybio Corporation is $8.16. The forecasts range from a low of $8.08 to a high of $8.40. Read More.
Extracted: $8.16, $8.08, $8.40Open source
RLYB Stock Ratings & Analyst Recommendations
Search result #4
This average target implies a growth of -5.1% compared to the current stock price of $8.43. Consensus Price Target. $1.00. Highest Price Target. $1.00 ...
Extracted: $8.43Open source
Rallybio Stock Price Forecast. Should You Buy RLYB?
Search result #5
The Rallybio Corporation stock price gained 0.357% on the last trading day (Thursday, 2nd Apr 2026), rising from $8.40 to $8.43. During the last trading day the ...
Extracted: $8.40, $8.43Open source
Rallybio (Nasdaq:RLYB) - Stock Analysis
Search result #7
Price Volatility. Low High RLYB Average Market Volatility Industry. Data ... Analyst price targets. Analyst Research Reports; Blue Matrix. Market Prices, 30 ...
Open source

Scenarios

Bull Target (Scenario probability)

$15 / p=20% prob

Base Target (Scenario probability)

$9 / p=50% prob

Bear Target (Scenario probability)

$4 / p=30% prob

Price $17 as of 2026-06-01

Nearest Scenario: Bull (∆ 11%)

Targets vs latest close: Bull -11% · Base -50% · Bear -76%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Short-term Catalysts

Next few weeks

Near-term leadership gap after Chief Medical Officer departure
2026-07-05
Rallybio disclosed the immediate departure of its CMO (Steven Ryder, M.D.) on 2026-03-31; this personnel change could slow clinical program execution or increase perceived execution risk in the coming quarters [#8-K-2026-03-31].
Prob 65% • Move -15% • Priced-in 60%

Long-term Catalysts

Months to a year

Advancement of RLYB116 development after positive Phase 1 data
2027-04-06
Rallybio reported positive Phase 1 data for RLYB116 demonstrating complete and sustained inhibition of terminal complement; progression decisions (e.g., IND-enabling activities or partnered development) over the next 12 months could materially re-rate value if a clear path to a Phase 2 program or partner emerges [#IR-undated].
Prob 35% • Move 60% • Priced-in 40%

Risks

Clinical execution and timing risk for RLYB116
Leadership/management turnover disrupting program timelines
Limited market liquidity and potential dilution need

Peers

Symbol	Summary
ANTX	Small-cap clinical-stage biotech with comparable market cap and rare-disease/clinical development risk profile.
MRKR	Early-stage therapeutics company focused on cell-based/immune programs; similar execution/catalyst sensitivity.
VTGN	Small-cap biotech with development-stage assets and limited cash runway dynamics similar to Rallybio.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: Rallybio Corp Common (RLYB) analyst consensus price target high low average
Analysis date: 2026-04-06